USRM (US Stem Cell) Accounts Payable: $1.63 Mil (As of Dec. 2022)


USRM US Stem Cell Inc USRM
12 GF Score
Price $0.00
View Full Analysis

What is US Stem Cell Accounts Payable?

US Stem Cell USRM -99.00% 12 Accounts Payable is $1.63 Mil as of Dec. 2022. GuruFocus rates USRM with a GF Score™ of 12/100.

US Stem Cell's Accounts Payable for the quarter that ended in Dec. 2022 was $1.63 Mil.

US Stem Cell's quarterly Accounts Payable increased from Jun. 2022 ($1.51 Mil) to Sep. 2022 ($1.57 Mil) and increased from Sep. 2022 ($1.57 Mil) to Dec. 2022 ($1.63 Mil).

US Stem Cell's annual Accounts Payable increased from Dec. 2020 ($1.28 Mil) to Dec. 2021 ($1.37 Mil) and increased from Dec. 2021 ($1.37 Mil) to Dec. 2022 ($1.63 Mil).

US Stem Cell Accounts Payable Historical Data

* Premium members only.

The historical data trend for US Stem Cell's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

US Stem Cell Accounts Payable Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.18 1.19 1.28 1.37 1.63

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 1.51 1.51 1.57 1.63
USRM
12GF Score
US Stem Cell Inc USRM
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

US Stem Cell Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $1.63 Mil mean?
US Stem Cell (USRM) has a Accounts Payable of $1.63 Mil as of Dec. 2022. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on US Stem Cell and its competitors.
Is US Stem Cell's Accounts Payable too high?
US Stem Cell's current Accounts Payable is $1.63 Mil. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's Accounts Payable compare to NOVNQ and RGRX?
US Stem Cell's Accounts Payable of $1.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on US Stem Cell and its competitors. US Stem Cell's current Accounts Payable is $1.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current Accounts Payable of $1.63 Mil. The current Accounts Payable is $1.63 Mil. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For US Stem Cell (USRM), the current Accounts Payable is $1.63 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

US Stem Cell Business Description

Address 1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score

Get the complete analysis for USRM

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price